Andrew O.

Manulife-HK is an active manager which offers locally managed Asian equity, fixed-income and global strategies based on fundamental research and quantitative modeling and analysis drawn from the parent firm in Canada. The firm's equity teams focus on delivering alpha via differentiated investment processes driven by proprietary fundamental research and a long-term orientation. They utilize multiple sources of alpha based on a fundamental, research-driven investment approach across traditional and non-traditional market sectors.

FrontPoint-Hong Kong is an active, research-based manager which employs multiple strategies, including a Japan long/short strategy and an Asia Pacific (including Japan) strategy. They utilize a combination of fundamental analysis and bottom-up stock picking to make investments. The firm believes that the FrontPoint investment management platform and equity-oriented culture enables them to enhance their primary research capabilities and maintain a sustainable competitive edge across Asian markets. They collaborate with other FrontPoint managers to share information and focus on applying FrontPoint's portfolio management software development capabilities and independent risk management framework to manage investments.

Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders